Former FDA Commissioner Hahn Faces Questions From House On Trump Interference, Other COVID Issues
Executive Summary
The request for an interview by the House Select Subcommittee on the Coronavirus Crisis seeks more information on the actions by President Trump and others to influence FDA decisions on HCQ, convalescent plasma, and vaccine decisions.
You may also be interested in...
Did The US FDA Mix Politics And Science With Its Cancer Guidance Announcement?
Three new guidances were announced the morning of President Biden’s State of the Union address, but experts said the move did not equate with past White House pressure on agency decisions.
Culture Wars Reach Labeling For COVID-19 Treatments
Senators ask US FDA to change statements in COVID-19 monoclonal antibody fact sheets that factors like race or ethnicity may place a patient high-risk of serious illness, saying they promote racist decisions.
The Case For US FDA To Be More Political In Its Approval Decisions
No one thinks it is a good idea for the US FDA Commissioner or some other higher up political actor to decide when and if to approve new drug applications. But it might not be so bad if the scientific staff at FDA paid a bit more attention to ‘political’ issues before making some decisions.